RenovoTAMP™ Technology: Innovative targeted chemotherapy delivery system.
Clinical Validation: Supported by recent publications and new studies.
Market Potential: Positioned within a projected $220.5 billion cancer therapy...
TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a...
NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90 is a pioneering...
NurExone (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone") is a pioneering biopharmaceutical company developing regenerative medicine therapies.
For a quick catch up on NRX, here are...
RenovoRx’s TAMP™ platform significantly increases local tissue concentration of chemotherapy, potentially reducing systemic side effects and enhancing treatment efficacy.
The Phase III TIGeR-PaC clinical trial...